An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) announced the release of its IVDR Class A instruments, kits, and reagents on May 26, 2022, aligning with the EU's In Vitro Diagnostic Regulation (IVDR). This transition allows labs in the EU to use Agilent products without interruption, enhancing patient safety and regulatory compliance. Agilent's Class A products encompass a wide range of solutions, addressing challenges posed by the COVID pandemic. The company reported $6.32 billion in revenue for fiscal 2021 and boasts a global workforce of 17,000.
Positive
Release of IVDR Class A products ensures uninterrupted usage in EU labs.
Commitment to patient safety and regulatory compliance.
Negative
None.
SANTA CLARA, Calif.--(BUSINESS WIRE)--
Agilent Technologies Inc. (NYSE: A) today announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR regulation.
This launch of IVDR-compliant Class A products ensures that labs in the EU who rely on Agilent IVDR instruments, kits, and reagents in their diagnostic workflows will continue to be able to use these products without disruption.
The In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746 is a new, harmonized regulatory framework established to ensure the present and future safety and performance of in vitro diagnostic (IVD) medical devices in the European Union market. The IVDR regulation replaces the previous IVDD directive, under which many Agilent products have been CE-IVD marked, indicating IVDD compliance. The launch represents a significant milestone for the Agilent organization, which faced substantial hurdles due to the COVID pandemic and related supply-chain challenges.
“Agilent shares the European Commission's vision of enhanced patient safety and transparency,” said Jenipher Dalton, senior vice president of Global Quality and Regulatory Affairs at Agilent. “We remain committed to providing high-quality solutions for delivering the testing results that physicians and patients in the EU rely on. Our multi-disciplinary team really came together to make this a seamless transition, and this result is a testament to their dedication and professionalism.”
Agilent Class A IVDR-compliant products span the entire Agilent product portfolio, from qPCR and NGS preparation instruments to H&E stains, staining instruments, and conjugated secondary antibody reagents.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
What did Agilent Technologies announce on May 26, 2022?
Agilent Technologies announced the release of IVDR Class A instruments, kits, and reagents, ensuring compliance with the EU's new In Vitro Diagnostic Regulation.
How does the IVDR Class A release benefit EU laboratories?
The IVDR Class A release allows EU laboratories to continue using Agilent's diagnostic products without disruption, enhancing safety and compliance.
What is the significance of Agilent's IVDR Class A products?
The IVDR Class A products mark a significant milestone for Agilent, enabling regulatory compliance amid challenges such as the COVID pandemic.
What was Agilent Technologies' revenue for fiscal 2021?
Agilent Technologies generated $6.32 billion in revenue for fiscal 2021.
